Author(s): Yap TA, Carden CP, Attard G, de Bono JS
Prostate cancer therapy for locally advanced and metastatic diseases includes androgen deprivation therapy (ADT). Second-generation antiandrogens have a role in castration-resistant prostate cancer. Nevertheless, some patients do not respond to this therapy, and eventually all the patients became resistant. This is due to modifications to intracellular signaling pathways, genomic alteration, cytokines production, metabolic switches, constitutional receptor activation, overexpression of some proteins, and regulation of gene expression. The aim of this review is to define the most important mechanisms that drive this resistance and the newest discoveries in this field, specifically for enzalutamide and abiraterone, with potential implications for future therapeutic targets. Furthermore, apalutamide and darolutamide share some resistance mechanisms with abiraterone and enzalutamide and could be useful in some resistance settings.
Referred From: https://www.mdpi.com/2076-3271/10/2/25/htm
Author(s): Huggins C, Hodges CV
Author(s): Sharifi N, Gulley JL, Dahut WL
Author(s): Byar DP
Author(s): Keating NL, O’Malley AJ, Smith MR
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al.
Author(s): Roach M, Bae K, Speight J, Wolkov HB, Rubin P, et al.
Author(s): Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, et al.
Author(s): Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, et al.
Author(s): Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR
Author(s): van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, et al.
Author(s): Martín-Merino E, Johansson S, Morris T, García Rodríguez LA
Author(s): http://www
Author(s): De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al.
Author(s): Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al.
Author(s): Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al.
Author(s): Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, et al.
